{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-23-000019","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.840129+00:00","generated_at":"2026-06-12T21:01:40.097228+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex Q2 product revenue $2.49B (+14% YoY); raises FY 2023 guidance to $9.7-9.8B","bullets":["Q2 product revenue $2.49B, up 14% vs Q2 2022; U.S. revenue $1.51B (+7%), OUS $985M (+26%).","Full-year CF product revenue guidance raised to $9.7-$9.8B from $9.55-$9.7B; R&D/SG&A guidance also raised.","FDA accepted exa-cel BLAs for SCD & TDT; Priority Review for SCD, PDUFA Dec 8, 2023; TDT PDUFA Mar 30, 2024.","Vanzacaftor triple SKYLINE & RIDGELINE studies expected to complete by end of 2023; results in early 2024.","VX-548 pivotal program in acute pain expected to complete late 2023; results late 2023/early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-23-000019","json":"https://secwatch.observer/filing/0000875320-23-000019.json","markdown":"https://secwatch.observer/filing/0000875320-23-000019.md","text":"https://secwatch.observer/filing/0000875320-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000019/0000875320-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000019/vrtx-20230801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:01:40.097228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50d444f315bc366585e606fd38220a4df167cfa8","claim":"VERTEX PHARMACEUTICALS INC / MA reported the second quarter ended June 30, 2023 results: revenue $2.49 billion. Guidance raised.","evidence_excerpt":"Vertex Reports Second Quarter 2023 Financial Results — Product revenue of $2.49 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000019/0000875320-23-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$2.49 billion"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}